XTANDI, also known by its generic name enzalutamide, is a prescription medication used in the treatment of certain types of prostate cancer. Specifically, it is indicated for patients with castration-resistant prostate cancer (CRPC), which is a form of prostate cancer that continues to progress despite the lowering of testosterone levels, which can be achieved through medical or surgical means. XTANDI works by inhibiting the action of male hormones, such as testosterone, on the prostate cancer cells, thereby slowing the growth and spread of the tumor. It is an oral medication, making it convenient for patients to take as part of their treatment regimen. XTANDI has been a significant advancement in the management of advanced prostate cancer, offering hope to many patients facing this challenging diagnosis.